Despite the attractiveness of EGFR as a target in GBM, clinical trials using EGFR TKIs developed for non-CNS primary indications have yielded disappointing results in GBM trials thus far, with no FDA-approved medications. The gene discussed is EGFR; the disease is glioblastoma.